H2L5186303

H2L5186303 is a potent and selective LPA2 receptor antagonist with an IC50 of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects[1][2][3].

Product Specifications

CAS Number

[139262-76-3]

UNSPSC

12352005

Target

Apoptosis; LPL Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/h2l5186303.html

Purity

98.24

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

OC(/C=C\C(NC(C=C1)=CC=C1OC2=CC=CC(OC3=CC=C(C=C3)NC(/C=C\C(O)=O)=O)=C2)=O)=O

Molecular Formula

C26H20N2O8

Molecular Weight

488.45

References & Citations

[1]Fells JI, et al. Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17 (21) :7457-64.|[2]Ye-Ji Lee, et al. Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice. Int J Mol Sci. 2022 Aug 28;23 (17) :9745.|[3]Zhongxing Liang, et al. Compensatory Upregulation of LPA2 and Activation of the PI3K-Akt Pathway Prevent LPA5-Dependent Loss of Intestinal Epithelial Cells in Intestinal Organoids. Cells. 2022 Jul 20;11 (14) :2243.|[4]Ishimoto K, et al. Rapid establishment of highly migratory cells from cancer cells for investigating cellular functions. J Recept Signal Transduct Res. 2019 Jun;39 (3) :194-198.